← Leaderboards
Charles Patrick Reynolds
Texas Tech University Health Scis Center
$10,127,129
Attributed
$11,502,533
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,502,533 · 12
By mechanism
R01$7,784,170 · 6
U01$1,833,412 · 1
P01$951,934 · 3
R21$933,017 · 2
Top collaborators
- Min Hee Kang6 shared
Others in their field
Top investigators on “Neuroblastoma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Gregory H Reaman · National Childhood Cancer Foundation$84,462,747
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$58,436,699
- Larry Arthur$30,516,306
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
NeuroblastomaTumorCell LineChemotherapyClinical TrialsResistanceMutationMalignant NeoplasmsBasePre-Clinical ModelTp53 GeneDna DamageMalignant Childhood NeoplasmResponseDrug ResistanceCancer CellLaboratoriesOverexpressionProteinsMolecularNew Therapeutic TargetPhenotypeBiological MarkersNovel Therapeutics
Grant awards (46)
Targeting Shared Vulnerabilities in Alternate Telomere Lengthening (ALT) Cancers$384,099
R01 · FY2025 · CA · contact PI
Robust assays to define telomere maintenance mechanisms as cancer biomarkers.$365,287
U01 · FY2025 · CA · contact PI
Targeting Shared Vulnerabilities in Alternate Telomere Lengthening (ALT) Cancers$364,894
R01 · FY2024 · CA · contact PI
Robust assays to define telomere maintenance mechanisms as cancer biomarkers.$336,904
U01 · FY2024 · CA · contact PI
Targeting Shared Vulnerabilities in Alternate Telomere Lengthening (ALT) Cancers$376,418
R01 · FY2023 · CA · contact PI
Robust assays to define telomere maintenance mechanisms as cancer biomarkers.$358,327
U01 · FY2023 · CA · contact PI
Targeting Shared Vulnerabilities in Alternate Telomere Lengthening (ALT) Cancers$384,099
R01 · FY2022 · CA · contact PI
Robust assays to define telomere maintenance mechanisms as cancer biomarkers.$360,176
U01 · FY2022 · CA · contact PI
Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targets$342,988
R01 · FY2022 · CA · contact PI
Robust assays to define telomere maintenance mechanisms as cancer biomarkers.$412,718
U01 · FY2021 · CA · contact PI
MYC activation in tumor progression of neuroblastoma$388,113
R01 · FY2021 · CA
Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targets$349,988
R01 · FY2021 · CA · contact PI
Alternate Telomere Maintenance Mechanisms in High Risk Neuroblastoma as Prognostic Indicators and Therapeutic Targets Yr 1 to 5$59,991
R01 · FY2021 · CA · contact PI
Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines$531,922
R01 · FY2020 · CA · contact PI
MYC activation in tumor progression of neuroblastoma$394,841
R01 · FY2020 · CA
Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targets$349,988
R01 · FY2020 · CA · contact PI
Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines$520,798
R01 · FY2019 · CA · contact PI
MYC activation in tumor progression of neuroblastoma$361,698
R01 · FY2019 · CA
Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targets$339,487
R01 · FY2019 · CA · contact PI
Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines$553,437
R01 · FY2018 · CA · contact PI
Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targets$349,988
R01 · FY2018 · CA · contact PI
A Phase I trial combining fenretinide and safingol to target overproduction of di$311,717
R21 · FY2012 · CA · contact PI
A Phase I trial combining fenretinide and safingol to target overproduction of di$323,700
R21 · FY2011 · CA · contact PI
Enhancing Activity of Alkylating Agents in Neuroblastoma$229,187
R01 · FY2011 · CA · contact PI
Enhancing Activity of Alkylating Agents in Neuroblastoma$1
R01 · FY2010 · CA · contact PI
RETINOID THERAPY$247,481
P01 · FY2009 · CA · contact PI
Enhancing Activity of Alkylating Agents in Neuroblastoma$231,069
R01 · FY2009 · CA · contact PI
Enhancing Activity of Alkylating Agents in Neuroblastoma$210,659
R01 · FY2008 · CA · contact PI
RETINOID THERAPY$182,528
P01 · FY2008 · CA · contact PI
RETINOID THERAPY$178,327
P01 · FY2007 · CA · contact PI
Enhancing Activity of Alkylating Agents in Neuroblastoma$62,346
R01 · FY2007 · CA · contact PI
Enhancing Activity of Alkylating Agents in Neuroblastoma$247,248
R01 · FY2006 · CA · contact PI
RETINOID THERAPY$174,248
P01 · FY2006 · CA · contact PI
Enhancing Activity of Alkylating Agents in Neuroblastoma$253,199
R01 · FY2005 · CA
RETINOID THERAPY$169,350
P01 · FY2005 · CA
Xenograft models of human neuroblastoma bone metastases.$148,800
R21 · FY2004 · CA
Xenograft models of human neuroblastoma bone metastases.$148,800
R21 · FY2003 · CA
Retinoid therapy$0
P01 · FY2002 · CA
Core--Digital image microscopy/flow cytometry$0
P01 · FY2002 · CA
ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA$234,734
R01 · FY2001 · CA
Core--Digital image microscopy/flow cytometry$0
P01 · FY2001 · CA
Retinoid therapy$0
P01 · FY2001 · CA
ENHANCING ACTIVITY OF ALKYLATING AGENTS IN NEUROBLASTOMA$227,899
R01 · FY2000 · CA
RETINOID THERAPY OF NEUROBLASTOMA$35,079
R01 · FY2000 · CA
Core--Digital image microscopy/flow cytometry$0
P01 · FY2000 · CA
Retinoid therapy$0
P01 · FY2000 · CA